Novartis tests drug to regrow Worn-Out knee cartilage
NCT ID NCT04097379
Summary
This study tested whether a new drug called LRX712, injected directly into the knee joint, could help regrow damaged cartilage in people with mild to moderate knee osteoarthritis. It was a small, early-stage trial involving 45 participants who received either the drug or a placebo over 8 weeks, followed by nearly a year of monitoring. The main goal was to see if the treatment was safe and if MRI scans showed signs of cartilage repair.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS (OA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Leiden, South Holland, 2333 CL, Netherlands
Conditions
Explore the condition pages connected to this study.